SCHEMBL353167

SCHEMBL353167

CN(Cc1csc(NC(=O)NCc2ccc(Cl)c(Cl)c2)n1)S(C)(=O)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 14/20 0.45
ROCK2 O75116 13/20 0.44
AKT1 P31749 2/20 0.44
GSK3B P49841 2/20 0.44
LIMK1 P53667 2/20 0.44
CDC42BPA Q5VT25 2/20 0.44
SGK1 O00141 1/20 0.44
TNK2 Q07912 1/20 0.44
DMPK Q09013 1/20 0.44
MYLK Q15746 1/20 0.44
MAPK1 P28482 3/20 0.42
AURKA O14965 1/20 0.42
DYRK3 O43781 1/20 0.42
PRKD3 O94806 1/20 0.42
PRKCG P05129 1/20 0.42
PRKACA P17612 1/20 0.42
RPS6KB1 P23443 1/20 0.42
MARK3 P27448 1/20 0.42
CSNK1D P48730 1/20 0.42
CLK2 P49760 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4726467 0.89 ROCK1 (0.47) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL354736 0.87 ROCK1 (0.46) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL4725225 0.84 SLC2A1 (0.43) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL4777144 0.84 ROCK1 (0.43) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL352910 0.84 P2RX7 (0.45) ROCK1ROCK2MAPK1TSHR
Hydrochloric Acid SCHEMBL4726458 0.83 SLC2A1 (0.43) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL4776684 0.83 ROCK1 (0.42) ROCK1ROCK2AKT1GSK3BLIMK1
Hydrochloric Acid SCHEMBL4956924 0.83 ROCK1 (0.42) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL352015 0.83 ROCK2 (0.58) ROCK1ROCK2AKT1GSK3BLIMK1
Hydrochloric Acid SCHEMBL4725350 0.83 ROCK1 (0.42) ROCK1ROCK2AKT1GSK3BLIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP claimed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO claimed
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA ROCK1 4747/4885ROCK2 4626/4885AKT1 3182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.